Granted Patent
B2
US 12,285,481 · App. 18/312,532 · Granted Apr 29, 2025
Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid protein
Assignee:
NantCell, Inc.
A61K39/215C07K14/005C07K14/165C12N1/16C12N15/86A61K38/00A61K39/235C07K14/8103C07K2317/52C07K2319/01C07K2319/06C12N2710/10341C12N2770/20034C12Y304/17023
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
Claims (12)
1. A method for inducing immunity in an individual, the method comprising administration to the individual a replication defective adenoviral serotype-5 (Ad5) vector comprising 1) an E1 gene region deletion, 2) an E2b gene region deletion, 3) a nucleic acid sequence that encodes a SARS-COV-2 S protein having the amino acid sequence of SEQ ID NO: 4, and 4) a nucleic acid sequence that encodes a chimeric protein comprising a SARS-COV-2 N protein having the amino acid sequence of SEQ ID NO: 1 and an endosomal targeting sequence having the amino acid sequence of SEQ ID NO: 2.
2. The method of claim 1 , further comprising administering a co-stimulatory molecule and/or an immune stimulatory cytokine.
3. The method of claim 2 , wherein the co-stimulatory molecule is selected from the group consisting of CD80, CD86, CD30, CD40, CD30L, CD40L, ICOS-L, B7-H3, B7-H4, CD70, OX40L, 4-IBBL, GITR-L, TIM-3, TIM-4, CD48, CD58, TLIA, ICAM-1, and LFA3.
4. The method of claim 2 , wherein the immune stimulatory cytokine is selected from the group consisting of IL-2, IL-12, IL-15, nogapendekin alfa-imbakicept, IL-21, IPS1, and LMP 1.
5. The method of claim 1 , wherein the individual is administered 1×10 10 to 1×10 11 viral particles (VP) per dose.
6. The method of claim 1 , wherein the Ad5 vector is administered orally, subcutaneously, or intravenously.
7. A method for preventing and/or treating COVID-19 in an individual, the method comprising administration to the individual a replication defective adenoviral serotype-5 (Ad5) vector comprising 1) an E1 gene region deletion, 2) an E2b gene region deletion, 3) a nucleic acid sequence comprising a portion that encodes a SARS-COV-2 S protein having the amino acid sequence of SEQ ID NO: 4; and 4) a nucleic acid sequence that encodes a chimeric protein comprising a SARS-COV-2 N protein having the amino acid sequence of SEQ ID NO: 1, and an endosomal targeting sequence having the amino acid sequence of SEQ ID NO: 2.
8. The method of claim 7 , further comprising administering a co-stimulatory molecule and/or an immune stimulatory cytokine.
9. The method of claim 8 , wherein the co-stimulatory molecule is selected from the group consisting of CD80, CD86, CD30, CD40, CD30L, CD40L, ICOS-L, B7-H3, B7-H4, CD70, OX40L, 4-IBBL, GITR-L, TIM-3, TIM-4, CD48, CD58, TLIA, ICAM-1, and LFA3.
10. The method of claim 8 , wherein the immune stimulatory cytokine is selected from the group consisting of IL-2, IL-12, IL-15, nogapendekin alfa-imbakicept, IL-21, IPS1, and LMP1.
11. The method of claim 7 , wherein the individual is administered 1×10 10 to 1×10 11 viral particles (VP) per dose.
12. The method of claim 7 , wherein the Ad5 vector is administered orally, subcutaneously, or intravenously.
Assignments (1)
SECURITY INTEREST
Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
Continuity (9)
Provisional Application
63022146
· May 8, 2020
Provisional Application
63016241
· Apr 27, 2020
Provisional Application
63016048
· Apr 27, 2020
Provisional Application
63010010
· Apr 14, 2020
Provisional Application
63009960
· Apr 14, 2020
Provisional Application
62991504
· Mar 18, 2020
Provisional Application
62988328
· Mar 11, 2020
References Cited (216)
US 6133036A
· Putcha et al.
· 2000
[cited by applicant]
US 6716392B1
· Putcha et al.
· 2004
[cited by applicant]
US 7618817B2
· Campbell
· 2009
[cited by applicant]
US 7750123B2
· Marasco et al.
· 2010
[cited by applicant]
US 8034332B2
· Klingemann
· 2011
[cited by applicant]
US 8313943B2
· Campbell
· 2012
[cited by applicant]
US 9150636B2
· Campbell
· 2015
[cited by applicant]
US 9181322B2
· Campbell
· 2015
[cited by applicant]
US 20040161388A1
· Liu et al.
· 2004
[cited by applicant]
US 20050003548A1
· Korokhov et al.
· 2005
[cited by applicant]
US 20060171962A1
· Enjuanes Sanchez et al.
· 2006
[cited by applicant]
US 20070105193A1
· Vilalta et al.
· 2007
[cited by applicant]
US 20100150923A1
· Jiang et al.
· 2010
[cited by applicant]
US 20100196411A1
· Duke et al.
· 2010
[cited by applicant]
US 20120076820A1
· Amara et al.
· 2012
[cited by applicant]
US 20120107347A1
· Hodge et al.
· 2012
[cited by applicant]
US 20120288502A1
· Diskin et al.
· 2012
[cited by applicant]
US 20130123136A1
· Abassi et al.
· 2013
[cited by applicant]
US 20160076053A1
· Jones et al.
· 2016
[cited by applicant]
US 20160168591A1
· Brennan et al.
· 2016
[cited by applicant]
US 20160223564A1
· Lee et al.
· 2016
[cited by applicant]
US 20170224794A1
· Franzusoff et al.
· 2017
[cited by applicant]
US 20170246276A1
· Palena et al.
· 2017
[cited by applicant]
US 20180244756A1
· Graham et al.
· 2018
[cited by applicant]
US 20180296663A1
· Hipp et al.
· 2018
[cited by applicant]
US 20190307819A1
· Drew et al.
· 2019
[cited by applicant]
US 20210284713A1
· Niazi et al.
· 2021
[cited by applicant]
US 20210284716A1
· Niazi et al.
· 2021
[cited by applicant]
CN 1488646A
· 2004
[cited by applicant]
CN 1572875A
· 2005
[cited by applicant]
CN 102844329A
· 2012
[cited by applicant]
CN 111249454A
· 2020
[cited by applicant]
CN 111254155A
· 2020
[cited by applicant]
CN 111330003A
· 2020
[cited by applicant]
CN 111375055A
· 2020
[cited by applicant]
EP 1508615A1
· 2005
[cited by applicant]
JP 2008505114A
· 2008
[cited by applicant]
JP 2019521148A
· 2019
[cited by applicant]
JP 2021167805A
· 2021
[cited by applicant]
KR 101453923B1
· 2014
[cited by applicant]
KR 20220006125A
· 2022
[cited by applicant]
WO 2003066820A2
· 2003
[cited by applicant]
WO WO03066820A2
· 2003
[cited by examiner]
WO 2005120565A2
· 2005
[cited by applicant]
WO 2006068663A2
· 2006
[cited by applicant]
WO 2006113214A2
· 2006
[cited by applicant]
WO 2009006479A2
· 2009
[cited by applicant]
WO 2011129468A1
· 2011
[cited by applicant]
WO 2012109404A1
· 2012
[cited by applicant]
WO 2014031178A1
· 2014
[cited by applicant]
WO 2016112188A1
· 2016
[cited by applicant]
WO 2016116398A1
· 2016
[cited by applicant]
WO 2018014008A1
· 2018
[cited by applicant]
WO 2018140456A1
· 2018
[cited by applicant]
WO 2018200389A1
· 2018
[cited by applicant]
WO 2019143606A1
· 2019
[cited by applicant]
WO 2020086745A1
· 2020
[cited by applicant]
WO 2020219974A1
· 2020
[cited by applicant]
WO 2021165448A1
· 2021
[cited by applicant]
WO 2021183665A1
· 2021
[cited by applicant]
WO 2021183717A1
· 2021
[cited by applicant]
WO 2021188599A1
· 2021
[cited by applicant]
WO 2021212021A2
· 2021
[cited by applicant]
WO 2021248853A1
· 2021
[cited by applicant]
WO 2021250467A2
· 2021
[cited by applicant]
WO 2021254287A1
· 2021
[cited by applicant]
WO 2022132625A1
· 2022
[cited by applicant]
Nilvebrant, J., and J. Rockberg, 2018, An introduction to epitope mapping, Meth. Mol. Biol. 1785:1-10.
[cited by examiner]
Sanchez-Trincado, J. L., et al., 2017, Fundamentals and methods for T- and B-cell epitope prediction, J. Immunol. Res. Article ID 2680160, pp. 1-14.
[cited by examiner]
Lavarone, C., et al., 2017, Mechanism of action of mRNA-based vectors, Exp. Rev. Vaccines 16(9):871-881.
[cited by examiner]
Robert-Guroff, M., 2007, Replicating and non-replicating viral vectors for vaccine development, Curr. Opin. Biotechnol. 18:546-556.
[cited by examiner]
Liniger, M., et al., 2008, Induction of neutralizing antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses, Vaccine 26:2164-2174.
[cited by examiner]
Wu, F., et al., Mar. 2020, A new coronavirus associated with human respiratory disease in China, Nature 579:265-269 and S1-15, published online Feb. 3, 2020.
[cited by examiner]
Wu, F., et al., Mar. 2020, Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome, GenBank MN908947.3, pp. 1-12.
[cited by examiner]
Liniger, M., et al., 2008, Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles virus, Vaccine 26:2164-2174.
[cited by examiner]
Enjuanes, L., et al., 2008, Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease, Vir. Res. 133:45-62.
[cited by examiner]
See, R. H., et al., 2006, Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus, J. Gen. Virol. 87:641-650.
[cited by examiner]
Chen et al., “Fusion protein linkers: property, design and functionality”, Adv Drug Deliv Rev, vol. 65, No. 10, 32 pages.
[cited by applicant]
Battle et al., “Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?”, Clinical Science, 2020, vol. 134, pp. 543-545.
[cited by applicant]
Kruse Robert L., “Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China [version 2; peerreview: 2 approved]”, F1000 Research, 2020, vol. 9, No. 7, 14 pages.
[cited by applicant]
Lu et al., “Arg15-Lys17-Arg18 Turkey Ovomucoid Third Domain Inhibits Human Furin”, The Journal of Biological Chemistry, 1993, vol. 268, No. 20, p. 14583-14585.
[cited by applicant]
Coutard et al., “The spike glycoprotein of the new coronavirus 2019-nCOV contains a furin-like cleavage site absent in CoV of the same Glade”, Antiviral Research, 2020, No. 176, 6 pages.
[cited by applicant]
Yao et al., “Polyethyleneimine-coating enhances adenoviral transduction of mesenchymal stem cells”, Biochemical and Biophysical Research Communications, 2014, vol. 447, No. 3, pp. 383-387.
[cited by applicant]
Yin et al., “[Measurement of subsets of blood T lymphocyte in 93 patients with severe acute respiratory syndrome and its clinical significance]”, Chinese Journal of Tuberculosis and Respiratory Diseases, 2003, vol. 26, …
[cited by applicant]
Lei et al., “Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig”, bioRxiv, 2020, 11 pages.
[cited by applicant]
Amalfitano et al., “Production and Characterization of Improved Adenovirus Vectors with the EI, E2b, and E3 Genes Deleted”, Journal of Virology, 1998, vol. 72, No. 2, pp. 926-933.
[cited by applicant]
Yan et al., “Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2”, Science, 2020, pp. 1-9.
[cited by applicant]
Zhang et al.“Angiotensin-converting enzyme 2(ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target”, Intensive Care Med, 2020, 5 pages.
[cited by applicant]
Zhonghua Yi Xue Za Zhi, “Dynamic Changes of T-lymphocytes and Immunoglobulins in Patients With Severe Acute Respiratory Syndrome”, Natl Med J China, Jun. 25, 2003, vol. 83, No. 12, pp. 1014-1017.
[cited by applicant]
“The Involvement of Natural Killer Cells in thePathogenesis of Severe Acute Respiratory Syndrome”, National Research Project for SARS, Beijing Group, American Journal of Clinical Pathology, 2004, vol. 121, pp. 507-511.
[cited by applicant]
Bergamaschi et al., “Intracellular Interaction of Interleukin-15 with Its Receptor alpha during Production Leads to Mutual Stabilization andIncreased Bioactivity”, The Journal of Biological Chemistry, 2008, vol. 283, No…
[cited by applicant]
Bessard et al., “High Antitumor Activity of RLI, an interleukin-15 (IL-15)-IL-15 Receptor Alpha Fusion Protein, in Metastatic Melanoma and Colorectal Cancer”, Mal Cancer Ther, 2009, vol. 8, No. 9, pp. 2736-2745.
[cited by applicant]
Chan et al., “A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster”, lancet, vol. 395, pp. 514-523.
[cited by applicant]
Clay et al., “Severe Acute Respiratory Syndrome-Coronavirus Infection in Aged Nonhuman Primates Is Associated With Modulated Pulmonary and Systemic Immune Responses”, Immunity & Ageing, 2014, vol. 11, No. 4, pp. 1-16.
[cited by applicant]
Dubois et al., “Preassociation of IL-15 With IL-15R alpha-IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T cells and its antitumor action”, The Journal of Immunology, 2008, vol. 180, pp. 2099-210…
[cited by applicant]
Duitman et al., “How a Cytokine Is Chaperoned Through the Secretory Pathway by Complexing With Its Own Receptor: Lessons From interleukin-15 (IL-15)/IL-15 Receptor Alpha”, molecular and Cellular Biology, Aug. 2008, vol.…
[cited by applicant]
Ellis-Connell et al., “ALT-803 Transiently Reduces Simian Immunodeficiency Virus Replication in the Absence of Akritiretroviral Treatment”, Journal of Virology, 2018, vol. 92, No. 3, pp. 1-21.
[cited by applicant]
Epardaud et al., “Interleukin-15/interleukin-15R Alpha Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T Cells”, Cancer Research, 2008, vol. 68, No. 8, pp. 2972-2983.
[cited by applicant]
Fehniger et al., “Interleukin-2 and interleukin-15: Immunotherapy for Cancer”, Cytokine Growth Factor Rev, 2002, vol. 13, No. 2, pp. 169-183.
[cited by applicant]
Furuya et al., “Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model”, Journal of translational Medicine, 2019, vol. 17, No. …
[cited by applicant]
Gomes-Giacoia et al., “Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; A Role for Cytokine Production and NK Cell Expansion”, Plos One, 2014, vol. 9, No. 6, …
[cited by applicant]
Guan et al., “Clinical Characteristics of Coronavirus Disease 2019 in China”, The New England Journal of Medicine, 2020, 13, pages.
[cited by applicant]
Guilliams et al., “The function of Fc gamma receptors in dendritic cells and macrophages”, Nature Reviews Immunology, 2014, vol. 14, pp. 94-108.
[cited by applicant]
Huang et al., “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”, Lancet, 2020, vol. 395, No. 10223, pp. 1-10.
[cited by applicant]
Huntington et al., “IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo”, Proceedings of the National Academy of Sciences, 2011, vol. 108, No. 15, pp. 6217-6…
[cited by applicant]
Jones et al., “A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes”, Plos Pathogens, 2016, pp. 1-25.
[cited by applicant]
Kim et al., “IL-15 superagonist/IL-15RaSushi-Fc Fusion Complex (IL-15SA/IL-15RaSu-Fc; ALT-803) Markedly Enhances Specific Subpopulations of NK and Memory CD8+ T Cells, and Mediates Potent Anti-Tumor Activity Against Mur…
[cited by applicant]
Law et al., “Chemokine Up-Regulation in SARS-coronavirus-infected, Monocyte-Derived Human Dendritic Cells”, Blood, 2005, vol. 106, No. 7, pp. 2366-2374.
[cited by applicant]
Mah et al., “Glycolytic Requirement for NK Cell Cytotoxicity and Cytomegalovirus Control”, JCI Insight, 2017, vol. 2, No. 23, 18 pages.
[cited by applicant]
Margolin et al., “Phase | Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients With Advanced Solid Tumors”, Clinical Cancer Research, 2018, vol. 24, No. 22, pp. 555-5561.
[cited by applicant]
Mathias et al., “Therapeutic Administration of IL-15 Superagonist Complex ALT-803 Leads to Long-Term Survival and Durable Antitumor Immune Response in a Murine Glioblastoma Model”, International Journal of Cancer, 2016,…
[cited by applicant]
Mcbrien et al., “Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells”, Nature, Feb. 6, 2020, vol. 578, pp. 154-159.
[cited by applicant]
Mortier et al., “Soluble Interleukin-15 Receptor a (IL-15Ra)-sushi as a Selective and Potent Agonist of IL-15 Action through IL-15R(3/y Hyperagonist IL-15-IL-15Ra Fusion Proteins”, Journal of Biological Chemistry, 2006,…
[cited by applicant]
Rhode et al., “Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models”, Cancer Immunol Res, 2016, vol. 4, pp. 1-12.
[cited by applicant]
Romee et al., “First-in-human Phase 1 Clinical Study of the IL-15 Superagonist Complex ALT-803 to Treat Relapse After Transplantation”, Blood, 2018, vol. 131, No. 23, pp. 2515-2527.
[cited by applicant]
Rosario et al., “The IL-15-Based ALT-803 Complex Enhances FcyRIlla-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas”, Clinical Cancer Research, 2016, vol. 22, No. 3, pp. 596-608.
[cited by applicant]
Seay et al., “In Vivo Activation of Human NK Cells by Treatment With an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice”, Journal of Virology, 2015, 46 pages.
[cited by applicant]
Spiegel et al., “Inhibition of Beta Interferon Induction by Severe Acute Respiratory Syndrome Coronavirus Suggests a Two-Step Model for Activation of Interferon Regulatory Factor 3”, Journal of Virology, 2005, vol. 79, …
[cited by applicant]
Waldmann Thomas A., “The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design”, Nature Reviews Immunology vol. 2006, vol. 6, pp. 595-601.
[cited by applicant]
Wang et al., “lgG Fc engineering to modulate antibody effector functions”, 2017, 11 pages.
[cited by applicant]
Webb et al., “The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles”, Blood Advances, 2018, vol. 2, No. 2, pp. 76-84.
[cited by applicant]
Weiss et al., “Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus”, Microbiology and molecular Biology Reviews, 2005, vol. 69, No. 4, 31 pages.
[cited by applicant]
Wrangle et al., “ALT-803, an IL-15 Superagonist, in Combination With Nivolumab in Patients With Metastatic Non- Small Cell Lung Cancer: A Non-Randomised, Open-Label, Phase 1 b Trial”, Lancet Oncol, 2018, vol. 19, No. 5,…
[cited by applicant]
Xu et al., “Efficacy and Mechanism-Of-Action of a Novel Superagonist interleukin-15: Interleukin-15 Receptor aSu/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma”, Cancer Research, 2013, vol. 73, No. 10,…
[cited by applicant]
Zhu et al. “Novel Human Interleukin-15 Agonists”, The Journal of Immunology, 2009, vol. 183, pp. 3598-3607.
[cited by applicant]
Zhu et al., “MHC Class I-Related Neonatal Fc Receptor for IgG Is Functionally Expressed in Monocytes, Intestinal Macrophages, and Dendritic Cells”, The Journal of immunology, 2001, vol. 166, pp. 3266-3276.
[cited by applicant]
Saiki et al., “Induction of Humoral Responses Specific for Paraneoplastic Cerebellar Degeneration-Associated Antigen by Whole Recombinant Yeast Immunization”, Journal of Autoimmunity, 2005, vol. 24, pp. 203-208.
[cited by applicant]
Lei et al., “Yeast Surface-Displayed H5N1 Avian Influenza Vaccines”, Hindawi publishing Corporation, 2016, pp. 1-12.
[cited by applicant]
Kim et al., “Oral Immunization With Whole Yeast Producing Viral Capsid Antigen Provokes a Stronger Humoral Immune Response Than Purified Viral Capsid Antigen”, Letters in Applied Microbiology, 2013, vol. 58, pp. 285-291.
[cited by applicant]
Safdari et al., “Use of Single-Chain Antibody Derivatives for Targeted Drug Delivery”, Molecular Medicine, 2016, vol. 22, pp. 258-270.
[cited by applicant]
“Sorrento Develops STI-4398 (COVIDTRAPTm PROTEIN) for Potential Prevention and Treatment of SARS-COV-2 Coronavirus Disease (COVID-19)”, Sorrento Therapeutics, 2020, 4 pages.
[cited by applicant]
Levin et al. Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol. Jan. 2015;33(1):27-34.
[cited by applicant]
Renegar et al. Role of IgA versus IgG in the Control of Influenza Viral Infection in the Murine Respiratory Tract. J Immunol. 2004; 173:1978-1986.
[cited by applicant]
Raftery et al., “Chitosan for Gene Delivery and Orthopedic TissueEngineering Applications”, Molecules, 2013, vol. 18, pp. 5611-5647.
[cited by applicant]
Cunningham et al., “Effective Long-term Preservation of Biological Evidence”, Bode Technology, 2014, 153 pages.
[cited by applicant]
Roth et al., “Functionalized Calcium Carbonate Microparticles for the Delivery of Proteins”, European Journal of Pharmaceutic,s and Biopharmaceutics, 2017, 38 pages.
[cited by applicant]
Rogers et al., “Isolation of potent SARS-COV-2 neutralizing antibodies and protection from disease in a small animal model”, Science, 2020, 12 pages.
[cited by applicant]
Wec et al., “Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARSCOV-2 spike protein”, Version 2. bioRxiv., 2020, 18 pages.
[cited by applicant]
Yuan et al., “A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV”, Science, 2020, vol. 368, pp. 1-4.
[cited by applicant]
Glasgow et al., “Engineered ACE2 receptor traps potently neutralize SARS-COV-2”, PNAS, 2020, 25 pages.
[cited by applicant]
Rice et al., “A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses”, BioRxiv, 2020, 36 pages.
[cited by applicant]
UniProtKB—Q9BYF1 (ACE2 H U Man), Aug. 2, 2005.
[cited by applicant]
See et al., “Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus”, Journal of General Virology, 2006, vol. 87, pp. 641-650.
[cited by applicant]
Sieling et al., “Th1 Dominant Nucleocapsid and Spike Antigen-Specific CD4+ and CD8+ Memory T CellRecall Induced by hAd5 S-Fusion + N-ETSD Infection of Autologous Dendritic Cells fromPatients Previously Infected with SAR…
[cited by applicant]
Gabitzsch et al., “Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challengeby Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to SubcutaneousPrime and Thermally-Stable Oral Boost Bivalent…
[cited by applicant]
Seif et al., “Yeast (Saccharomyces cerevisiae) Polarizes Both M-CSF- and GM-CSF-Differentiated Macrophages Toward an M1-Like Phenotype”, Inflammation, 2016, 14 pages.
[cited by applicant]
Biondo et al., “Recognition of yeast nucleic acids triggers a host-protective type I interferon response”, Eur. J. Immunol., 2011, vol. 41, pp. 1969-1979.
[cited by applicant]
International Search Report and Written Opinion received for PCT Application Serial No. PCT/1B2021/054887 dated Sep. 6, 2021, 13 pages.
[cited by applicant]
Khodaei et al., “Covalent Immobilization of Protein A on Chitosan and Aldehyde Double-Branched Chitosan as Biocompatible Carriers for Immunoglobulin G (Igg) Purification”, Journal of Chromatographic Science, 2018, pp. 1…
[cited by applicant]
Byrnes et al., “A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding”, medRxiv, 2020, 23 pages.
[cited by applicant]
Wang et al., “A human monoclonal antibody blocking SARS-COV-2 infection”, Nature Communications, 2020, vol. 11, No. 2251, pp. 1-6.
[cited by applicant]
International Search Report and Written Opinion received for PCT Application Serial No. PCT/US2021/021737 dated Jun. 25, 2021, 11 pages.
[cited by applicant]
Zhao et al., “Identification and characterization of dominant helper T-cell epitopes in the nucleocapsid protein of severe acute respiratory syndrome coronavirus”, Journal of Virology, 2007, vol. 81, No. 11, pp. 6079-60…
[cited by applicant]
Gabitzsch et al., “Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [EI-, E2b-]-CEA”, Cancer Immunology Immunotherapy, 2010, vol. 59, pp. 1131-1135.
[cited by applicant]
Fan et al., “The nucleocapsid protein of coronavirus infectious bronchitis virus: crystal structure of its N-terminal domain and multimerization properties”, Structure, 2005, vol. 13, pp. 1859-1868.
[cited by applicant]
International Search Report and Written Opinion received for PCT Application Serial No. PCT/US2021/021819 dated Jun. 21, 2021, 20 pages.
[cited by applicant]
Oi-Wing et al.,“Substitution at Aspartic Acid 1128 in the SARSCoronavirus Spike Glycoprotein Mediates Escape from aS2 Domain-Targeting Neutralizing Monoclonal Antibody”, Plos one, 2014, vol. 9, No. 7, pp. 1-11.
[cited by applicant]
Pak et al., “Structural Insights into Immune Recognition of theSevere Acute Respiratory Syndrome Coronavirus SProtein Receptor Binding Domain”, Journal of Molecular Biology, 2009, vol. 388, pp. 815-823.
[cited by applicant]
Park et al., “Spike protein binding prediction with neutralizing antibodies of SARS-COV-2”, bioRxiv , 2020, 22 pages.
[cited by applicant]
Tripp et al., “Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): Identification of neutralizing and antibodies reactive to S, N, M and E viral proteins”, Journal of Virological Methods, 2005, vol. 128, pp…
[cited by applicant]
Zheng et al., “Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2”, Eurosurveillance, 2020, vol. 25, No. 28, pp. 19-28.
[cited by applicant]
Pietravalle et al., “Cleavage of membrane-bound CD40 ligand is not required for inducing B cell proliferation and differentiation”, Eur. J. Immunol, vol. 26, 1996, pp. 725-728.
[cited by applicant]
Tan, Y. W., et al., Amino acid residues critical for RNA-binding in the N-terminal domain of the nucleocapsid protein are essential determinants for the infectivity of coronavirus in cultured cells, Nucleic Acids Res. 3…
[cited by applicant]
Lin, H.- X., et al., 2008, Identification of residues in the receptor-binding domain (RBD) of the spike protein of human coronavirus NL63 that are critical for the RBD-ACE2 receptor interaction, J. Gen. Virol. 89:1015-1…
[cited by applicant]
Lu, Y., et al., 2008, Importance of SARS-CoV spike protein Trp-rich region in viral infectivity, Biochem. Biophys. Res. Comm. 371: 356-360.
[cited by applicant]
Guo, Y., et al., 2009, Identification of a new region of Sars-CoV S protein critical for viral entry, J. Mol. Biol. 394:600-605.
[cited by applicant]
Bhatti, J. S., et al., Nov. 2020, Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection, Mol. Neurobiol., DOI: 10. 1007/s12035-020-02074-2, published online Aug. 18, 202…
[cited by applicant]
Rice et al., “Intranasal plus subcutaneous prime vaccination with a dual antigen COVID 19 vaccine elicits T cell and antibody responses in mice” Scientific Reports, (2021) 11:14917 p. 1-15.
[cited by applicant]
Zhou, W., et al., 2023, Vaccines' New Era-RNA Vaccine, Viruses 15, 1760, pp. 1-19.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Application Serial No. PCT/IB2021/054887 dated Feb. 2, 2023, 6 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Application Serial No. PCT/US2021/021737 dated Sep. 6, 2022, 6 pages.
[cited by applicant]
Office Action received in Canada Patent Application Serial No. 3170513 dated Aug. 21, 2023, 5 pages.
[cited by applicant]
Office Action received in Canada Patent Application Serial No. 3170513 dated Oct. 22, 2024, 3 pages.
[cited by applicant]
Extended European Search Report received in European Patent Application Serial No. 21768699.7 dated Mar. 18, 2024, 15 pages.
[cited by applicant]
Enjuanes, L. et al. (2008) Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Research, vol. 133, No. 1, 45-62, ISSN: 0168-1702, DOI: 10.1016/J.VIRUSRES.2007.01.021.
[cited by applicant]
Shi, J. et al. (2015) Epitope-based vaccine target screening against highly pathogenic Mers-CoV: an in silico approach applied to emerging infectious diseases. PLOS ONE, vol. 10, No. 12, e0144475, US ISSN: 1932-6203, DO…
[cited by applicant]
Abdelzaher, H. M., et al., 2021, RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement, Vaccines 9: 1-23.
[cited by applicant]
Partial Supplementary European Search Report received in European Patent Application Serial No. 21846127.5 dated Aug. 2, 2024, 14 pages.
[cited by applicant]
Bosnjak Berislav et al.: “Low serum neutralizing anti-SARS-COV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods”, Cellular & Molecular Immunology, vol. 18…
[cited by applicant]
Abe Kento T. et al.: “A simple protein-based surrogate neutralization assay for SARS-CoV-2”, JCI Insight, vol. 5, No. 19, Oct. 2, 2020 (Oct. 2, 2020), XP055780531, ISSN: 2379-3708, DOI: 10.1172/jci.insight. 142362 Retri…
[cited by applicant]
Edward P. Gniffke et al.: “Plasma from recovered COVID19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay.”, MEDRXIV, Jun. 11, 2020 (Jun. 11, 2020), XP055769440, DOI: 10.1101/2020.…
[cited by applicant]
Tan Chee Wah et al.: “A SARS-COV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction”, Nature Biotechnology, Nature Publishing Group US, New York, vol. 38,…
[cited by applicant]
Extended European Search Report received in European Patent Application Serial No. 21846127.5 dated Nov. 5, 2024, 16 pages.
[cited by applicant]
Rosales-Mendoza Sergio et al.: “What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?”, Vaccines, vol. 8, No. 2, Apr. 14, 2020 (Apr. 14, 2020), p. 183, XP093151469, CH ISSN: 2076-393X, DOI: 10.33…
[cited by applicant]
Wang Ning et al.: “Aluminum Nanoparticles Acting as a Pulmonary Vaccine Adjuvant-Delivery System (VADS) Able to Safely Elicit Robust Systemic and Mucosal Immunity”, Journal of Inorganic and Organometallic Polymers and M…
[cited by applicant]
First Examination Report received in Australia Patent Application Serial No. 2021236141 dated Apr. 9, 2024, 5 pages.
[cited by applicant]
Notice of Acceptance for Patent Application received in Australia Patent Application Serial No. 2021236141 dated May 17, 2024, 3 pages.
[cited by applicant]
First Examination Report received in Australia Patent Application Serial No. 2021312381 dated May 22, 2024, 4 pages.
[cited by applicant]
Second Examination Report received in Australia Patent Application Serial No. 2021312381 dated Jun. 24, 2024, 5 pages.
[cited by applicant]
Third Examination Report received in Australia Patent Application Serial No. 2021312381 dated Sep. 4, 2024, 3 pages.
[cited by applicant]
Fourth Examination Report received in Australia Patent Application Serial No. 2021312381 dated Oct. 8, 2024, 8 pages.
[cited by applicant]
Ali, Amanat, et al., Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms', 2020, Scientific reports, vol. 10(1), pages (2020), Article 14214.
[cited by applicant]
Fukushi, Shuetsu., 'Competitive ELISA for the detection of serum antibodies specific for middle east respiratory syndrome coronavirus (MERS-COV)', 2020, Coronaviruses: Methods and Protocols, pp. 55-65.
[cited by applicant]
Neumann MM , Volodkin D . Porous antibody-containing protein microparticles as novel carriers for ELISA. Analyst. Feb. 1, 20207;145(4): 1202-1206. doi: 10.1039/c9an01888c. PMID: 31859691.
[cited by applicant]
Zhuang, Wei, et al. “Sensitive and portable electrochemical immunoassay for lipoprotein-associated phospholipase A 2 using BSA-doped CaCO 3 nanospheres to regulate pH readout.” Analytical Methods 11.12 (2019): 1631-1638.
[cited by applicant]
Peng J, Feng LN, Zhang K, Li XH, Jiang LP, Zhu JJ. Calcium carbonate-gold nanocluster hybrid spheres: synthesis and versatile application in immunoassays. Chemistry. Apr. 2, 20123;18(17):5261-8. doi: 10.1002/chem.201102…
[cited by applicant]
Mou, Huihui et al. “Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2.” bioRxiv : the preprint server for biology 2020.06.29.178459. Jun. 30, 2020, doi: 10.1101/2020.06.29.178459. P…
[cited by applicant]
Request for the Submission of an Opinion received in Korea Patent Application Serial No. 10-2023-7006003 dated Oct. 25, 2024, 11 pages (including English Translation).
[cited by applicant]
Seth J. zost et al., nature, (Jul. 15, 2020), vol. 584, and the pp. 443-449.
[cited by applicant]
First Office Action received in China Patent Application Serial No. 202180020795.0 dated Jun. 19, 2024, 18 pages.
[cited by applicant]
Notice of Reasons for Refusal received in Japan Patent Application Serial No. 2022-554944 dated Dec. 26, 2023, 11 pages.
[cited by applicant]
Decision of Refusal received in Japan Patent Application Serial No. 2022-554944 dated Aug. 2, 2024, 6 pages.
[cited by applicant]
Notice of Reasons for Refusal received in Japan Patent Application Serial No. 2023-503132 dated Aug. 13, 2024, 13 pages.
[cited by applicant]
Lee, Y., et al., Oct. 2023, Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics, Exp. Mol. Med. 55:2085-2096.
[cited by applicant]
Hou, X., et al., Dec. 2021, Lipid nanoparticles for mRNA delivery, Nat. Rev. Mat. 6:1078-1094.
[cited by applicant]
Sharon D., and A. Kamen, 2018, Advancements in the design and scalable production of viral gene transfer vectors, Biotechnology and Bioengineering, 115:25-40.
[cited by applicant]
Second Office Action received in China Patent Application Serial No. 202180020795.0 dated Jan. 22, 2025, 9 pages.
[cited by applicant]